Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.500
-0.010 (-0.66%)
Dec 5, 2025, 4:00 PM EST - Market closed
Inhibikase Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
181.90M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IKT News
- 15 days ago - Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 15 days ago - Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 15 days ago - Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension - GlobeNewsWire
- 21 days ago - Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 3 months ago - Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer - GlobeNewsWire
- 4 months ago - Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 7 months ago - Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 8 months ago - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewsWire